Neurocrine Biosciences, Inc.
NBIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $341,300 | $249,700 | $154,500 | $89,600 |
| Dep. & Amort. | $27,100 | $21,300 | $15,600 | $10,900 |
| Deferred Tax | -$123,100 | -$56,700 | $19,100 | $4,300 |
| Stock-Based Comp. | $195,500 | $194,300 | $173,100 | $134,200 |
| Change in WC | -$19,200 | $28,200 | -$67,400 | $16,700 |
| Other Non-Cash | $173,800 | -$46,900 | $44,500 | $800 |
| Operating Cash Flow | $595,400 | $389,900 | $339,400 | $256,500 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$38,200 | -$28,300 | -$16,500 | -$23,400 |
| Net Acquisitions | $0 | $0 | -$42,700 | $0 |
| Inv. Purchases | -$1,056,100 | -$1,411,200 | -$628,900 | -$804,700 |
| Inv. Sales/Matur. | $967,500 | $972,400 | $511,000 | $697,900 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$126,800 | -$467,100 | -$177,100 | -$130,200 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$308,800 | $0 | -$279,000 | -$100 |
| Stock Issued | $122,100 | $65,300 | $44,700 | $27,500 |
| Stock Repurch. | -$300,000 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $0 | $0 | $0 |
| Financing Cash Flow | -$486,700 | $65,300 | -$234,300 | $27,400 |
| Forex Effect | $0 | $300 | -$1,300 | $0 |
| Net Chg. in Cash | -$18,100 | -$11,600 | -$73,300 | $153,700 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $259,100 | $270,700 | $344,000 | $190,300 |
| End Cash | $241,000 | $259,100 | $270,700 | $344,000 |
| Free Cash Flow | $557,200 | $361,600 | $322,900 | $233,100 |